Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Oncoinvent ASA's Debt-to-Equity or its related term are showing as below:
CHIX:ONCINo'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.07
Current: 0.02
During the past 11 years, the highest Debt-to-Equity Ratio of Oncoinvent ASA was 0.07. The lowest was 0.00. And the median was 0.00.
CHIX:ONCINo's Debt-to-Equity is ranked better than 87.75% of 955
companies
in the Biotechnology industry
Industry Median: 0.16
vs CHIX:ONCINo: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Oncoinvent ASA Debt-to-Equity Related Terms
Oncoinvent ASA Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Oncoinvent ASA's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ONCINO vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Oncoinvent ASA's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoinvent ASA Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Oncoinvent ASA's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoinvent ASA (CHIX:ONCINO) has a Debt-to-Equity of 0.03 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Oncoinvent ASA and its competitors. According to the industry distribution chart, Oncoinvent ASA ranks #117 out of 955 companies in the Biotechnology industry, placing it in the top 12.3%.
Is Oncoinvent ASA's Debt-to-Equity too high?
Oncoinvent ASA's current Debt-to-Equity is 0.03. The Biotechnology industry median Debt-to-Equity is 0.16. Oncoinvent ASA's value of 0.03 is 81.3% below this industry median. Based on the distribution chart, Oncoinvent ASA ranks #117 out of 955 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oncoinvent ASA has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncoinvent ASA ranks #117 out of 955 companies for Debt-to-Equity. This places Oncoinvent ASA in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Oncoinvent ASA's value of 0.03 is 81.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncoinvent ASA's current Debt-to-Equity of 0.03 is 81.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Oncoinvent ASA and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncoinvent ASA's current Debt-to-Equity is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (CHIX:ONCINO) has a current Debt-to-Equity of 0.03. The stock's GF Value™ is kr11,480.05, compared to a current price of kr1,039.91 — trading 90.9% below its estimated fair value. The current Debt-to-Equity is 0.03 and 81.3% below the Biotechnology industry median of 0.16. Oncoinvent ASA's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Oncoinvent ASA (CHIX:ONCINO), the current Debt-to-Equity is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued.
The current stock price of kr1,039.91 is trading 90.9% below its estimated GF Value™ of kr11,480.05.
Key valuation signals for CHIX:ONCINO:
Debt-to-Equity: 0.03
GF Value™: kr11,480.05 vs. price of kr1,039.91 (90.9% below fair value)
Industry Position: 81.3% below the Biotechnology median (#117 of 955)
No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
44GF Score
Get the complete analysis for CHIX:ONCINO
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONCINO has been successfully added to your 
